Peter Xaysanasy

Founder/R&D technology officer:(1)Develop a patented ELG-3 method in glucose & A1C analysis, an equivalent too OTC blood sugar [IFCC]/A1C [NGSP] meters (FDA approved [2018] 510k market, Class II)
(2) Drug/Repurposing of 4-MU in acute lung injury & acute respiratory distress syndrome; (i) NIH/CERF/MCM'S-FDA/Pre-IND submission, a joint corroboration animal efficacy study, (ii) FDA/IND pending an EUA in Covid-19.
(3) Proof of concept- using our patented ELG-3 method, a Prion (PrPse) 'infectious ' a scintillation detector-rapid, cost effective, in the field use; in live-stocks, food chains, for Chronic Wasting Disease CWD, CFD.
(4) ELISA/clonal anti-bodies; an early dx in ALI&ARDS progression